Oral News and Research

RSS

Esperion Therapeutics reports positive results from ETC-1002 Phase 2a study for LDL-C treatment

Esperion Therapeutics, Inc., a clinical-stage biopharmaceutical company, today announced positive top-line results from a Phase 2a study of ETC-1002 when added to statin therapy in patients with elevated levels of low density lipoprotein cholesterol (LDL-C or "bad cholesterol").

4 Sep 2013

Research shows how mucosal surfaces in body respond to C. albicans to prevent damage

Candida albicans is a common fungus found living in, and on, many parts of the human body. Usually this species causes no harm to humans unless it can breach the body's immune defences, where can lead to serious illness or death.

3 Sep 2013

NPS MedicineWise reiterates safety messages around newer oral anticoagulants

NPS MedicineWise is reiterating safety messages around the newer anticoagulants dabigatran (Pradaxa) and apixaban (Eliquis) following their PBS listing for preventing stroke on 1 September 2013 – and again for rivaxabaran (Xarelto) which was PBS listed in August for the same purpose.

2 Sep 2013

Mass screening programme of 75-76 year olds to identify undiagnosed AF

Stroke is the second cause of death worldwide. Atrial fibrillation is the most common clinically relevant cardiac arrhythmia in Europe, affecting approximately 1.5-2% of the general population.1 Prevalence is estimated to double in the next 50 years as the population ages.

2 Sep 2013

Debiopharm starts Debio 1347 phase I study in patients with advanced solid tumors

Debiopharm Group, the Swiss-based global biopharmaceutical company that focuses on the development of prescription drugs that target unmet medical needs including oncology, today announced the start of a phase I, open label multicenter study of a selective FGFR 1, 2, 3 inhibitor, Debio 1347 (CH5183284) in patients with advanced solid tumors.

2 Sep 2013

Use of anticoagulant does not reduce ischemic events among patients undergoing PCI

Use of the novel anticoagulant otamixaban did not reduce ischemic events compared with unfractionated heparin plus eptifibatide but increased bleeding among patients with non-ST-segment elevation acute coronary syndromes undergoing a percutaneous coronary intervention (PCI; procedures such as balloon angioplasty or stent placement used to open narrowed coronary arteries), according to a study published by JAMA.

2 Sep 2013

Pre-treatment with prasugrel increases risk of bleeding without reducing risk of ischemic events

In patients with non-ST-elevation acute coronary syndrome (NSTE- ACS), pre-treatment with the P2Y12 antagonist prasugrel prior to catheterization, significantly increases the risk of life-threatening bleeding without reducing the risk of major ischemic events, according to the results of the ACCOAST (A Comparison of Prasugrel at PCI or Time of Diagnosis of Non-ST Elevation Myocardial Infarction) trial.

2 Sep 2013

Researchers pinpoint ways to counter effects of antibiotics-driven depletion of gut-dwelling bacteria

A new study by researchers at the Stanford University School of Medicine could help pinpoint ways to counter the effects of the antibiotics-driven depletion of friendly, gut-dwelling bacteria.

2 Sep 2013

Research: General practitioners undertreat women with atrial fibrillation

General practitioners (GPs) undertreat women with atrial fibrillation (AF), according to research presented at ESC Congress 2013 today by Dr Pierre Sabouret from France. The analysis of more than 15,000 patients showed that women were undertreated with antithrombotic medications compared to men regardless of their stroke risk and comorbidities.

2 Sep 2013

Okana acquires North American product rights for FACTIVE tablets from Merus Labs International

Okana Ventures Inc. is pleased to announce the acquisition of the North American product rights for FACTIVE® (Gemifloxacin Mesylate) tablets from Merus Labs International for approximately US$3.4 million.

31 Aug 2013

Nutritional supplements provided to inpatients linked with reductions in length of stay, hospitalization cost

A recent health economics and outcomes study, conducted by leading health economists and supported by Abbott, found that oral nutritional supplements provided to patients during hospitalization were associated with significant reductions in length of stay and hospitalization cost.

31 Aug 2013

Virtual surgical planning technologies for most challenging facial reconstruction cases

Virtual surgical planning technologies give surgeons a powerful new tool for their most challenging facial reconstruction cases, reports a paper in the September issue of Plastic and Reconstructive Surgery-, the official medical journal of the American Society of Plastic Surgeons (ASPS).

30 Aug 2013

HSS, UCSF and Mayo Clinic to validate new MRI techniques, biomarkers for osteoarthritis treatment

In recent years, researchers have been frustrated because there are no tools to identify early stages of osteoarthritis and thus no good way to test therapies for preventing or slowing the disease. Now, three institutions have been awarded $1 million from the Arthritis Foundation to validate the use of new MRI (magnetic resonance imaging) techniques and newly identified biomarkers to solve this vexing problem.

30 Aug 2013

Targeted Medical Pharma launches new division to manufacture and distribution dietary supplements

Targeted Medical Pharma, Inc., a biotechnology company that develops and distributes prescription medical foods to physicians and pharmacies, today announced the launch of a new division that will specialize in the manufacturing and distribution of a proprietary line of dietary supplements.

30 Aug 2013

Mallinckrodt to present MNK-795 clinical data at PAINWeek 2013

Mallinckrodt announced today that the first clinical data on MNK-795 will be presented at PAINWeek 2013, to be held September 4-7 in Las Vegas. MNK-795 is an extended-release oral formulation of oxycodone and acetaminophen that has been studied in clinical trials for the management of moderate to severe acute pain where the use of an opioid analgesic is appropriate.

29 Aug 2013

FDA approves NDA filing for ibrutinib inhibitor in two B-cell malignancies

Pharmacyclics, Inc. (Nasdaq: PCYC) today announced that the U.S. Food and Drug Administration (FDA) has accepted for filing its New Drug Application (NDA) for the investigational oral Bruton's tyrosine kinase (BTK) inhibitor ibrutinib, for two B-cell malignancy indications: previously treated mantle cell lymphoma (MCL) and previously treated chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL).

29 Aug 2013

Reformulated OxyContin®: an interview with Dr. Paul Coplan, Executive Director, Risk Management and Epidemiology, Purdue Pharma

OxyContin contains oxycodone, which is an opioid agonist. It is used for the management of moderate to severe pain when a constant opioid analgesic is needed for a prolonged period of time.

29 Aug 2013

Experts share tips on preventing ovarian cancer

Ovarian cancer is the fourth leading cause of death in American women. Approximately 22,000 women are diagnosed annually and 14,000 die from the disease. September is Ovarian Cancer Awareness month and Mount Sinai experts are sharing tips on prevention.

29 Aug 2013

Oral sunscreens not as effective as traditional lotions and creams, warns Loyola dermatologist

While it might be nice to pop a pill to protect your skin from the sun, a Loyola University Health System dermatologist warns that oral sunscreens are not as effective as traditional lotions and creams.

29 Aug 2013

New clinical recommendations urge women to maintain periodontal health during pregnancy

When a woman becomes pregnant, she knows it is important to maintain a healthy lifestyle to ensure both the health of herself and the health of her baby. New clinical recommendations from the American Academy of Periodontology and the Eurpean Federation of Periodontology urge pregnant women to maintain periodontal health as well.

29 Aug 2013

Oral News and Research

Esperion Therapeutics reports positive results from ETC-1002 Phase 2a study for LDL-C treatment

Research shows how mucosal surfaces in body respond to C. albicans to prevent damage

NPS MedicineWise reiterates safety messages around newer oral anticoagulants

Mass screening programme of 75-76 year olds to identify undiagnosed AF

Debiopharm starts Debio 1347 phase I study in patients with advanced solid tumors

Use of anticoagulant does not reduce ischemic events among patients undergoing PCI

Pre-treatment with prasugrel increases risk of bleeding without reducing risk of ischemic events

Researchers pinpoint ways to counter effects of antibiotics-driven depletion of gut-dwelling bacteria

Research: General practitioners undertreat women with atrial fibrillation

Okana acquires North American product rights for FACTIVE tablets from Merus Labs International

Nutritional supplements provided to inpatients linked with reductions in length of stay, hospitalization cost

Virtual surgical planning technologies for most challenging facial reconstruction cases

HSS, UCSF and Mayo Clinic to validate new MRI techniques, biomarkers for osteoarthritis treatment

Targeted Medical Pharma launches new division to manufacture and distribution dietary supplements

Mallinckrodt to present MNK-795 clinical data at PAINWeek 2013

FDA approves NDA filing for ibrutinib inhibitor in two B-cell malignancies

Reformulated OxyContin®: an interview with Dr. Paul Coplan, Executive Director, Risk Management and Epidemiology, Purdue Pharma

Experts share tips on preventing ovarian cancer

Oral sunscreens not as effective as traditional lotions and creams, warns Loyola dermatologist

New clinical recommendations urge women to maintain periodontal health during pregnancy

Advancing Neuroscience Research Through Collaboration and Patient-Centered Innovation

The impact of vibration on microscopy

How Omics Technologies Are Transforming Biological Research and Drug Discovery

Latest News